aTyr Pharma Inc (LIFE)
1.58
+0.01
(+0.64%)
USD |
NASDAQ |
May 01, 16:00
1.585
0.00 (0.00%)
After-Hours: 20:00
aTyr Pharma Cash from Investing (Quarterly): 17.82M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.82M |
| September 30, 2023 | 4.383M |
| June 30, 2023 | -4.156M |
| March 31, 2023 | -38.17M |
| December 31, 2022 | 1.999M |
| September 30, 2022 | 20.65M |
| June 30, 2022 | 9.971M |
| March 31, 2022 | 14.63M |
| December 31, 2021 | -49.35M |
| September 30, 2021 | -14.85M |
| June 30, 2021 | -3.974M |
| March 31, 2021 | -23.40M |
| December 31, 2020 | 3.203M |
| September 30, 2020 | 1.74M |
| June 30, 2020 | -9.449M |
| March 31, 2020 | 11.41M |
| December 31, 2019 | -1.22M |
| September 30, 2019 | 7.209M |
| June 30, 2019 | 2.291M |
| March 31, 2019 | -3.355M |
| Date | Value |
|---|---|
| December 31, 2018 | -2.133M |
| September 30, 2018 | 20.73M |
| June 30, 2018 | 7.162M |
| March 31, 2018 | 11.41M |
| December 31, 2017 | -3.53M |
| September 30, 2017 | -39.76M |
| June 30, 2017 | 11.25M |
| March 31, 2017 | 4.399M |
| December 31, 2016 | 8.602M |
| September 30, 2016 | 6.688M |
| June 30, 2016 | 3.845M |
| March 31, 2016 | 14.39M |
| December 31, 2015 | 3.904M |
| September 30, 2015 | 7.238M |
| June 30, 2015 | -84.96M |
| March 31, 2015 | 1.827M |
| December 31, 2014 | 2.75M |
| September 30, 2014 | 0.65M |
| June 30, 2014 | -0.038M |
| March 31, 2014 | -5.608M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-49.35M
Minimum
Dec 2021
20.65M
Maximum
Sep 2022
-2.593M
Average
1.999M
Median
Dec 2022
Cash from Investing (Quarterly) Benchmarks
| Vaxart Inc | 15.10M |
| Allogene Therapeutics Inc | 67.46M |
| AIM ImmunoTech Inc | -0.214M |
| Protalix BioTherapeutics Inc | -0.342M |
| Armata Pharmaceuticals Inc | -2.39M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -11.06M |
| Cash from Financing (Quarterly) | 6.034M |
| Free Cash Flow | -37.44M |
| Free Cash Flow Per Share (Quarterly) | -0.1868 |
| Free Cash Flow Yield | -44.10% |